title: [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
abstract: OBJECTIVE
  To reveal prognostically significant factors affecting efficacy of glivek therapy in untreated (duration of the disease < or = 6 months) and pretreated (duration of the disease > 6 months) patients with chronic myeloid leukemia (CML) in a chronic phase.
  
  
  METHODS
  A total of 338 patients (64 untreated and 274 pretreated) with a chronic-phase CML on glivek therapy entered the trial.
  
  
  RESULTS
  Five-year survival on glivek was high (89, 98 and 88% in untreated and pretreated patients, respectively). Incidence of transformation in the acceleration phase and blast crisis was low both in untreated and pretreated patients (1.6 and 11%, respectively) and correlated with the rate of a complete cytogenetic response (CCR). Untreated patients had no factors affecting treatment efficacy negatively, CCR probability was 96%. Blastemia, thrombocytosis and splenomegaly reduced CCR probability significantly in pretreated patients. Slow reduction of the tumor mass, late achievement of a complete hematological response and a cytogenetic response decreased probability of CCR.
  
  
  CONCLUSIONS
  Glivek is a drug of choice for patients with chronic-phase CML. High probability of CCR both in untreated and pretreated patients lowers the risk of the disease transformation into the phase of acceleration/blast crisis and raises overall survival in both groups.
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Zaritskiĭ
authors.forename: E G
authors.initials: EG
authors.lastname: Lomaia
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Vinogradova
authors.forename: G A
authors.initials: GA
authors.lastname: Druzhkova
authors.forename: T I
authors.initials: TI
authors.lastname: Kolosheĭnova
authors.forename: S S
authors.initials: SS
authors.lastname: Loria
authors.forename: T I
authors.initials: TI
authors.lastname: Pospelova
authors.forename: I V
authors.initials: IV
authors.lastname: Krylova
authors.forename: S S
authors.initials: SS
authors.lastname: Kruglov
authors.forename: S V
authors.initials: SV
authors.lastname: Kuznetsov
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Chelysheva
authors.forename: E M
authors.initials: EM
authors.lastname: Abakumov
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolova
authors.forename: I S
authors.initials: IS
authors.lastname: Nemchenko
authors.forename: E S
authors.initials: ES
authors.lastname: Zakharova
authors.forename: S R
authors.initials: SR
authors.lastname: Goriacheva
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Kolosova
authors.forename: M V
authors.initials: MV
authors.lastname: Vakhrusheva
authors.forename: A S
authors.initials: AS
authors.lastname: Liamkina
authors.forename: O A
authors.initials: OA
authors.lastname: Chernova
authors.forename: E R
authors.initials: ER
authors.lastname: Machiulaĭtene
authors.forename: V L
authors.initials: VL
authors.lastname: Ivanova
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Udal'eva
authors.forename: T V
authors.initials: TV
authors.lastname: Shneĭder
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Ogorodnikova
authors.forename: V S
authors.initials: VS
authors.lastname: Zhuravlev
authors.forename: A V
authors.initials: AV
authors.lastname: Zakharova
authors.forename: I S
authors.initials: IS
authors.lastname: Martynkevich
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'ev
authors.forename: K M
authors.initials: KM
authors.lastname: Abdulkadyrov
authors.forename: L G
authors.initials: LG
authors.lastname: Kovaleva
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000453:epidemiology / Q000473:pathology; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases